These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 12390542)

  • 41. Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.
    Nacsa J; Radaelli A; Edghill-Smith Y; Venzon D; Tsai WP; Morghen Cde G; Panicali D; Tartaglia J; Franchini G
    Vaccine; 2004 Jan; 22(5-6):597-606. PubMed ID: 14741150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques.
    Mitchell WM; Torres J; Johnson PR; Hirsch V; Yilma T; Gardner MB; Robinson WE
    AIDS; 1995 Jan; 9(1):27-34. PubMed ID: 7893438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccine-induced CD4+ T cells against the simian immunodeficiency virus gag protein. Epitope specificity and relevance to protective immunity.
    Mills KH; Barnard AL; Williams M; Page M; Ling C; Stott EJ; Silvera P; Taffs F; Kingsman AS; Adams SE
    J Immunol; 1991 Nov; 147(10):3560-7. PubMed ID: 1719081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
    Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI
    J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques.
    Venet A; Bourgault I; Aubertin AM; Kiény MP; Levy JP
    J Immunol; 1992 May; 148(9):2899-908. PubMed ID: 1349322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles.
    Mossman SP; Pierce CC; Watson AJ; Robertson MN; Montefiori DC; Kuller L; Richardson BA; Bradshaw JD; Munn RJ; Hu SL; Greenberg PD; Benveniste RE; Haigwood NL
    AIDS Res Hum Retroviruses; 2004 Apr; 20(4):425-34. PubMed ID: 15157361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.
    Egan MA; Charini WA; Kuroda MJ; Schmitz JE; Racz P; Tenner-Racz K; Manson K; Wyand M; Lifton MA; Nickerson CE; Fu T; Shiver JW; Letvin NL
    J Virol; 2000 Aug; 74(16):7485-95. PubMed ID: 10906202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contrasting effects of low-dose IL-2 on vaccine-boosted simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251.
    Nacsa J; Edghill-Smith Y; Tsai WP; Venzon D; Tryniszewska E; Hryniewicz A; Moniuszko M; Kinter A; Smith KA; Franchini G
    J Immunol; 2005 Feb; 174(4):1913-21. PubMed ID: 15699118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239.
    Abel K; Rourke T; Lu D; Bost K; McChesney MB; Miller CJ
    J Infect Dis; 2004 Nov; 190(9):1697-705. PubMed ID: 15478078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Control of Heterologous Simian Immunodeficiency Virus SIV
    Singh S; Ramírez-Salazar EG; Doueiri R; Valentin A; Rosati M; Hu X; Keele BF; Shen X; Tomaras GD; Ferrari G; LaBranche C; Montefiori DC; Das J; Alter G; Trinh HV; Hamlin C; Rao M; Dayton F; Bear J; Chowdhury B; Alicea C; Lifson JD; Broderick KE; Sardesai NY; Sivananthan SJ; Fox CB; Reed SG; Venzon DJ; Hirsch VM; Pavlakis GN; Felber BK
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29793957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.
    Amos JD; Himes JE; Armand L; Gurley TC; Martinez DR; Colvin L; Beck K; Overman RG; Liao HX; Moody MA; Permar SR
    J Virol; 2015 Sep; 89(18):9485-98. PubMed ID: 26157116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced safety and efficacy of live attenuated SIV vaccines by prevaccination with recombinant vaccines.
    Jones L; Ahmad S; Chan K; Verardi P; Morton WR; Grant R; Yilma T
    J Med Primatol; 2000 Aug; 29(3-4):231-9. PubMed ID: 11085585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Robust, vaccine-induced CD8(+) T lymphocyte response against an out-of-frame epitope.
    Maness NJ; Wilson NA; Reed JS; Piaskowski SM; Sacha JB; Walsh AD; Thoryk E; Heidecker GJ; Citron MP; Liang X; Bett AJ; Casimiro DR; Watkins DI
    J Immunol; 2010 Jan; 184(1):67-72. PubMed ID: 19949108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD8 T cell response maturation defined by anentropic specificity and repertoire depth correlates with SIVΔnef-induced protection.
    Adnan S; Colantonio AD; Yu Y; Gillis J; Wong FE; Becker EA; Piatak M; Reeves RK; Lifson JD; O'Connor SL; Johnson RP
    PLoS Pathog; 2015 Feb; 11(2):e1004633. PubMed ID: 25688559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques.
    Mortara L; Gras-Masse H; Rommens C; Venet A; Guillet JG; Bourgault-Villada I
    J Virol; 1999 May; 73(5):4447-51. PubMed ID: 10196344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Substitutions in a major histocompatibility complex class II-restricted human immunodeficiency virus type 1 gp120 epitope can affect CD4+ T-helper-cell function.
    Lekutis C; Letvin NL
    J Virol; 1998 Jul; 72(7):5840-4. PubMed ID: 9621044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells.
    Shimizu T; Uenishi H; Teramura Y; Iwashiro M; Kuribayashi K; Tamamura H; Fujii N; Yamagishi H
    J Virol; 1994 Dec; 68(12):7704-8. PubMed ID: 7525983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?
    Klasse PJ; Ozorowski G; Sanders RW; Moore JP
    Cell Host Microbe; 2020 Apr; 27(4):507-518. PubMed ID: 32272076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.